Related Experiment Video

Updated: Jul 4, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Molecular testing for somatic mutations in common cancers: the views of UK oncologists

S Wordsworth1, J Buchanan, I Papanicolas

  • 1Health Economics Research Centre, Department of Public Health, University of Oxford, Oxford, UK. sarah.wordsworth@dphpc.ox.ac.uk

Journal of Clinical Pathology
|May 29, 2008
PubMed
Abstract

Insights

Somatic mutation testing shows promise for improving cancer care, but widespread adoption faces barriers. Oncologists commonly use immunohistochemistry and fluorescent in situ hybridization, driven by available treatments.

Area of Science:

  • Oncology
  • Genetics
  • Clinical Pathology

Background:

  • Somatic mutations significantly influence cancer behavior and treatment response.
  • Molecular testing for somatic mutations is underutilized in clinical practice despite targeted therapy advancements.

Purpose of the Study:

  • To investigate current patterns and perceptions of somatic mutation testing among UK oncologists and hematologists.
  • To understand factors influencing test requests and future demand.

Main Methods:

  • A postal questionnaire was distributed to 582 UK oncologists and hematologists.
  • A 20% response rate was achieved, providing insights into current practices.

Main Results:

  • Immunohistochemistry (70%) and fluorescent in situ hybridization (55%) are the most frequent tests, particularly for breast cancer.
  • Treatment availability is the primary driver for testing decisions (62%).
  • Positive outlook for future demand in immunohistochemistry, FISH, microarray, and DNA tests, with uncertainty for microsatellite instability and ploidy testing.

Conclusions:

  • Somatic mutation testing is perceived to positively impact oncology, hematology, and patient care through improved classification and treatment.
  • Key barriers include insufficient scientific evidence and funding.
  • Further research is needed on service delivery models and resource implications to support increased demand.

More Related Videos

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology11:20

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...